Form 4: Progyny Director Cheryl Scott Sells Shares Under Pre-Arranged Trading Plan

Progyny, Inc. Director Cheryl Scott has reported the sale of 2,675 shares of common stock at a price of $22.07 per share, executed under a Rule 10b5-1 trading plan.

Summary

• Cheryl Scott, a Director at Progyny, Inc. (PGNY), sold 2,675 shares of the company's common stock.
• The transaction occurred on June 11, 2025, at a price of $22.07 per share.
• Following this sale, Ms. Scott beneficially owns 14,112 shares of Progyny common stock.
• The sale was conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan, indicating it was scheduled in advance.

Sentiment

Score: 5

Explanation: The sentiment is neutral. A Form 4 filing reports a factual insider transaction. The sale was conducted under a Rule 10b5-1 plan, which indicates it was pre-scheduled and not based on new, non-public information, thus mitigating potential negative sentiment often associated with insider selling.

Positives

• The transaction was executed under a Rule 10b5-1 trading plan, which suggests the sale was pre-scheduled and not based on new, non-public information, potentially mitigating negative market perception.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence or a move to diversify holdings, though the latter is often the case for directors.

Risks

• While a 10b5-1 plan reduces the signaling risk, any insider selling can still lead to minor negative sentiment or speculation among investors regarding the company's near-term prospects.
• The reduction in a director's direct ownership stake, even if small, could be viewed as a slight decrease in alignment with shareholder interests, though this is common for compensation and diversification.

Future Outlook

This Form 4 filing is a disclosure of an insider transaction and does not contain any forward-looking statements or guidance regarding Progyny's future financial performance or strategic outlook.

Industry Context

This specific insider transaction by a director of Progyny, Inc. is a routine disclosure and does not inherently reflect broader industry trends or competitive dynamics within the fertility benefits management sector. Insider sales are common for diversification or liquidity purposes, especially when executed under pre-arranged plans.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the director's direct ownership, which is a routine event for diversification or liquidity. The impact on overall share structure is negligible given the small number of shares relative to total outstanding.

Key Dates

Keywords

Progyny, PGNY, Insider Trading, Form 4, Stock Sale, Director, Cheryl Scott, 10b5-1 Plan, Beneficial Ownership, SEC Filing